Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2014; 20(10): 2695-2703
Published online Mar 14, 2014. doi: 10.3748/wjg.v20.i10.2695
Table 1 Characteristics of the included studies and patients on cytomegalovirus in ulcerative colitis
Ref.Year of publicationTypeDesignn
Included patientsSeverity criteriaMethod of diagnosisAnti-viral txFollow-up (mo)Short-term colectomy rate
Long-term colectomy rate
TXCTXCTXC
Omiya et al[8]2010FullP11010Moderate to severe UCSeo’s scoreTissue PCR (IHC/HE -)GCV120/100/103/100/10
Zeki et al[9]12010AbstractR2710UC (no severity data)NAHE/IHC+GCV-5,124/77/104/77/10
VGCV-2
Maconi et al[10]32011AbstractR2614Moderate to severe UCMayo/Baron scoreHE/IHC+GCV120/60/140/62/13
Criscuoli et al[17]2011FullP1721Moderate to severe UCTruelove/WittsIHC +, pp65+GCV-5 FC-2122/74/212/74/18
Kim et al[12]2012FullP11417Moderate to severe UCMayo/Baron scoreHE/IHC/PCR+GCVhospitalization3/140/17NANA
Roblin et al[13]32011FullP188Moderate to severe UC, failure of CS +rescue therapy (IFX/CSA)MayoqPCR, IHC/HE-GCV≥ 101/82/83/82/8
Al-Zafiri et al[14]32012FullR278Hospitalized UCNAIHC/HE+GCVhospitalization3/70/8NANA
Maruyama et al[15]2012AbstractR2412Moderate to severe UCNAIHC/HE+GCVHospitalization3/40/12NANA
Kopylov et al[16]2013FullR276UCNAIHC/HE+GCV-6 VGCV-1131/70/63/70/6
Table 2 Quality of studies on cytomegalovirus in ulcerative colitis assessed according to modified New-Castle Ottawa Scale
TotalOutcomeComparabilitySelectionRef.
1*Al-Zafiri et al[14], 2012
3***Criscuoli et al[17], 2011
4****Kim et al[12], 2012
1*Kopylov et al[16], 2013
3***Maconi et al[10], 2011
3***Maruyama et al[15], 2012
4****Omiya et al[8], 2010
4****Roblin et al[13], 2011
1*Zeki et al[9], 2010
24/54 (44.4%)4/9 (44.4%)4/18 (22.2%)16/27 (59.3%)Total